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Commentary
Last two decades of  research has seen the emergence and pro-
gress of  stem cells from a myth to reality and their expediency in 
the clinical perspective as an effective therapeutic modality. De-
spite immense progress and promising results from experimental 
animal studies and clinical trials, the provocative underlying mech-
anism of  their functional efficacy has led to diverging opinions 
and indulging the researchers into a continuous discussion. With 
controversies clouding the potential of  stem cells to adopt mor-
pho functionally competent cardiac phenotype, paracrine activity 
of  the transplanted stem cells has been put forth as an alternative 
mechanism associated with the beneficial outcome of  cell therapy. 
Although unique paracrine activity of  a cell, besides endocrine 
activity and juxtacrine activity, constitutes an integral part of  the 
cell-to-cell communication, the release of  trophic factors from 
the transplanted cells favorably modulates the local microenvi-
ronment in the cell transplanted region in the infarcted heart and 
positively impact the integration and reparability of  the cell graft. 
Besides, the donor cells via their paracrine activity provide a con-
ducive microenvironment for the host cardiac cells and enhance 
their survival via initiation of  survival signaling. Additionally, the 
paracrine trophic factors create a chemical gradient to promote 
extravasation of  bone marrow derived stem/progenitor cells into 
peripheral circulation for ultimate homing-in to the injured myo-
cardium along with the resident cardiac stem cells to participate in 
the repair process. The use of  paracrine factor-rich conditioned 
medium has also been used as an adjunct to cell therapy to en-
hance the engraftment of  the donor cells in the heart [1]. Despite 
wide acceptance of  the paracrine hypothesis and publication of  
a plethora of  studies that depict the release of  a wide-array of  
trophic factors by various stem/progenitor cells including the 
bone marrow derived mesenchymal stem cells (MSCs), there is 
no single study published as yet that comprehensively profiles 
their paracrine activity. The secretome is cell-type dependent and 
is unique for each cell type under a given set of  its culture condi-
tions. For example, the composition of  secretome of  bone mar-
row derived MSCs cultured under hypoxic conditions varies with 
the level of  oxygen [2]. Besides being affluent in growth factors 
and cytokines, recent studies have reported the shedding of  ex-
osomes as part of  their paracrine activity [3]. Exosomes are extra-
cellular vesicles of  endocytic origin and with less than 100 nm di-
ameter and enriched in proteins and microRNAs [4]. Microarray 
profiling of  the exosomes for their contents showed that MSCs 
use exosomes as carriers to deliver a distinct array of  microRNAs 
to the neighboring cells as part of  their mircine activity under giv-
en set of  conditions [5, 6]. Transplantation of  MSCs or injection-
based delivery of  their derivative exosomes help in transfer of  the 
microRNAs many of  which have significant role in physiological 
functioning of  cardiomyocytes at molecular and cellular levels as 
well as in the repair of  the infarcted myocardium [7].
An important step forward in the exploitation of  paracrine hy-
pothesis is the cell-free therapeutic interventional approach 
wherein conditioned medium in toto or its fractionated compo-
nents such as growth factors and exosomes from the bone mar-
row derived progenitor cells is used to treat the ischemic heart. 
The importance of  the cell-free therapy is to exploit the trophic 
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factor-rich conditioned medium that may be directly injected in 
and around the infarcted heart under direct vision at multiple in-
jection sites [8]. Alternatively, systemic administration of  condi-
tioned medium is carried out at multiple stipulated time-points 
for sustenance of  the therapeutic benefits for longer period of  
time. The promise of  cell-free strategy also alleviates the difficulty 
of  optimal cell types, its source and in vitro culture besides immu-
nological rejection of  donor cell graft post engraftment. As the 
conditioned medium can be stored, it’s off-the-shelf  availability 
also addresses the logistic concerns associated with the use of  
cell-based therapy.
The recent study published in IJTS by Amirfarghani et al., (2016) 
has signified the protective effects of  the bone marrow derived 
MSC conditioned medium in rabbit heart model of  experimen-
tally induced myocardial infarction [8]. The model was developed 
by coronary artery ligation followed by direct intramyocardial 
injection of  either in vitro expanded MSCs or their derivative 
conditioned medium in the infarcted myocardium. Transtho-
racic echocardiography at 1, 4 and 8 weeks after the respective 
treatment revealed sustained preservation of  left ventricular 
contractile function and attenuated remodeling of  the infarcted 
heart. The authors have discussed the altered serum levels of  Tu-
mor necrosis factor-α (TNF-α), Interleukin-6 (IL-6) and Tumor 
growth factor-β (TGF-β) in the animals at different time-points 
after their respective treatment with MSCs or their derivative con-
ditioned medium and have attributed to the beneficial effect of  
either treatment approach. The observed attenuated expression 
of  TGF-β in the study is a desirable feature of  the both MSCs 
as well as conditioned medium treatment as TGF-β is involved 
in each component of  the myocardial remodeling after infarction 
episode including cardiomyocyte apoptosis, fibrogenesis and my-
ocardial hypertrophy [9]. However, the elevated level of  TGF-β 
during the early phase of  infarction is cardio-protective and pro-
tects the heart against early phase inflammatory response [10]. 
On the contrary, levels of  IL-6 show a curved elevation profile 
earlier on during acute myocardial infarction and correlates well 
with C-reactive protein (CRP) expression indicating its impact as 
a mediator of  the early phase inflammatory response [11]. Similar 
to other members of  the family, IL-6 imparts its cytoprotective 
effects through downstream activation of  STAT3 with its pos-
sible interplay with ERK1/2 in different cell types [12, 13]. For 
example, pre-treatment of  HUVEC with recombinant IL-6 and 
IL-11 significantly enhanced their survival upon subsequent ex-
posure to oxidative stress [12]. Cardiomyocyte specific knock-
down of  STAT3 results in higher level of  inflammation sensitivity 
and increase cardiac fibrosis [14]. The cytoprotective effects of  
the both IL-6 and IL-11 have been attributed to STAT3 signal-
ing besides the involvement of  microRNA-21 [15]. TNF-α is a 
pro-inflammatory cytokine and a key modulator of  any inflamma-
tory response during acute phase myocardial injury [16]. Released 
by various cell types including macrophages and monocytes, the 
cardiac fibroblasts and cardiomyocytes have also been implicated 
as source of  TNF-α in the event of  ischemic injury to the myo-
cardium with as yet undefined mechanism [17, 18]. In vitro studies 
have shown that prolonged exposure of  cardiomyocytes activates 
HIF-1α dependent signaling in the cells to promote expression of  
secretion of  TNF-α [19]. There is a close interplay between the 
three cytokines in temporal fashion that oversee the events that 
follow any infarction episode [20]. A more in-depth mechanis-
tic study would help to understand the importance of  regulating 
their expression using MSC conditioned medium.
Although the data of  the published study [8] is interesting, it is 
not without its limitations. Protein expression level profiling of  
the conditioned medium for the presence of  the three reported 
cytokines and their expression level changes in the myocardium 
at stipulated time-points would have been interesting. Similarly, 
complete profiling of  growth factors in the conditioned medium 
would have immensely added to the impact of  study results. Addi-
tionally, there is little information about the molecular mechanism 
by which cell-free conditioned medium from MSCs regulated the 
interplay between the three cytokines and their time-dependent 
expression in the event of  myocardial infarction. An in-depth 
mechanistic study is therefore needed to address these issues such 
that the trio of  cytokines can be exploited as possible therapeutic 
target in the infarcted heart using cell-free conditioned medium 
of  the stem/progenitor cells.
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